Skip to main content
Edward Libby, MD, Oncology, Seattle, WA, UW Medicine/University of Washington Medical Center

EdwardNLibbyMD

Oncology Seattle, WA

Hematologic Oncology

Associate Professor, Medicine, University of Washington School of Medicine

Dr. Libby is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Libby's full profile

Already have an account?

Summary

  • Dr. Libby received his B.S. from the University of Texas at El Paso and his M.D. from the University of Texas Health Science Center at Houston. He completed his Internal Medicine residency and chief residency at the University of New Mexico(UNM) in Albuquerque. He was a Fellow in Hematology at UNM and at UNC Chapel Hill.

    Specialty & Clinical Expertise
    Multiple myeloma, Plasma cell leukemia, Amyloidosis (all types), Waldenstrom’s macroglobulinemia, Plasmacytomas, POEMS Syndrome, smoldering multiple myeloma, MGUS.

    Research Interests
    Dr. Libby is the primary investigator for numerous Phase I,II and III clinical trials in multiple myeloma, amyloidosis and Waldenstrom's macroglobulinemia.

Education & Training

  • University of New Mexico School of Medicine
    University of New Mexico School of MedicineFellowship, Hematology, 2002 - 2005
  • University of New Mexico School of Medicine
    University of New Mexico School of MedicineResidency, Internal Medicine, 1984 - 1987
  • McGovern Medical School at UTHealth
    McGovern Medical School at UTHealthClass of 1984

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2011 - 2022
  • NM State Medical License
    NM State Medical License 1985 - 2013
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
    Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
    Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Treating Cancer Differently in Older Patients
    Treating Cancer Differently in Older PatientsSeptember 10th, 2015

Professional Memberships

Hospital Affiliations